This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

Wall Street traders sent stocks lower in the run-up to the Federal Reserve decision, with concerns about high valuations ...

Wall Street traders sent stocks lower in the run-up to the Federal Reserve decision, with concerns about high valuations ...

September S&P 500 E-Mini futures (ESU25) are trending up +0.24% this morning, extending yesterday’s gains, while investors ...

Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug Administration that it could resume shipping a drug it paused sales of last week.

Analysts’ view on the stock has dramatically changed over the past few months. Currently, only 21% of the 29 analysts ...

The FDA’s top vaccine and gene therapy official resigned amid heightened scrutiny over recent drug approval decisions and ...

What's next for the stock market? Dow and Nasdaq futures rise as investors await Big Tech earnings and interest rate decision ...

Investors braced for the Federal Reserve's next interest rate decision and earnings from tech giants Microsoft and Meta.

FDA recommends lifting the hold on Sarepta's gene therapy Elevidys for ambulatory patients after investigation; ...

The Fed is expected to keep rates steady, but Powell will get questions on Fed independence. Apple, Microsoft, Meta and ...

Investor attention is shifting from geopolitics to corporate fundamentals as earnings begin to eclipse tariffs as the primary market catalyst, according to Barclays (LON:BARC).